EXELIXIS, INC.
About EXELIXIS, INC.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2026
- $2.3B
- Net income
- $782.6M
- Total assets
- $2.8B
- Market cap
- $13.2B
- Gross margin
- 96.5%
- Operating margin
- 27.9%
- Net margin
- 24.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2B
- Cost of revenue
- $76.2M
- Gross profit
- $2.1B
- Operating expenses
- $1.5B
- Operating income
- $604.6M
- Income tax
- $160.4M
- Net income
- $521.3M
- EPS (basic)
- $1.80
- EPS (diluted)
- $1.76
Balance sheet
- Total assets
- $2.9B
- Current assets
- $1.5B
- Total liabilities
- $703.5M
- Current liabilities
- $403.8M
- Shareholders’ equity
- $2.2B
Cash flow
- Operating cash flow
- $700.0M
- Investing cash flow
- -$116.8M
- Financing cash flow
- -$628.8M
- Net cash flow
- -$45.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.2B
- P/E ratio
- 29.4
- EPS (diluted)
- $1.76
- Shares outstanding
- 256.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 11, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $782.6M in FY2026.
- Revenue grew 124% from FY2019 to FY2024.
- Gross margin of 96.5%, net margin 24.0%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 29.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EXELIXIS, INC..
Write a review
News about EXELIXIS, INC.
News & sentiment via Polygon.io
